AB Corporate Bond ETF (NASDAQ:EYEG) Short Interest Update

by · The Markets Daily

AB Corporate Bond ETF (NASDAQ:EYEG – Get Free Report) saw a large decline in short interest during the month of June. As of June 15th, there was short interest totaling 100 shares, a decline of 34.6% from the May 31st total of 153 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 142 shares, the short-interest ratio is currently 0.7 days.

AB Corporate Bond ETF Stock Performance

AB Corporate Bond ETF stock traded down $0.04 during mid-day trading on Friday, reaching $35.19. The company’s stock had a trading volume of 40 shares, compared to its average volume of 216. The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01. AB Corporate Bond ETF has a twelve month low of $34.82 and a twelve month high of $36.63. The business has a 50 day moving average price of $35.22 and a 200-day moving average price of $35.52. The firm has a market cap of $28.15 million, a price-to-earnings ratio of -20.94 and a beta of 0.17.

AB Corporate Bond ETF Cuts Dividend

The firm also recently disclosed a monthly dividend, which will be paid on Tuesday, July 7th. Investors of record on Wednesday, July 1st will be given a dividend of $0.1358 per share. This represents a c) dividend on an annualized basis and a dividend yield of 4.6%. The ex-dividend date of this dividend is Wednesday, July 1st. AB Corporate Bond ETF’s dividend payout ratio is currently -102.98%.

Institutional Trading of AB Corporate Bond ETF

Large investors have recently modified their holdings of the company. Kestra Advisory Services LLC acquired a new stake in shares of AB Corporate Bond ETF in the fourth quarter valued at approximately $34,000. Jane Street Group LLC acquired a new position in shares of AB Corporate Bond ETF during the 2nd quarter valued at $232,000. Finally, Wealth Enhancement Advisory Services LLC raised its position in AB Corporate Bond ETF by 32.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 157,702 shares of the specialty pharmaceutical company’s stock worth $5,634,000 after acquiring an additional 38,685 shares in the last quarter. Institutional investors and hedge funds own 64.16% of the company’s stock.

About AB Corporate Bond ETF

(Get Free Report)

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

Read More